<DOC>
	<DOCNO>NCT00620802</DOCNO>
	<brief_summary>CG106 Phase I open-label , randomize , multiple-dose , two-way crossover study characterize pharmacodynamics pharmacokinetics investigational fixed-dose combination product CGT 2168 ( clopidogrel , 75 mg omeprazole , 20 mg ) relative Plavix® ( clopidogrel , 75 mg ) . Healthy volunteer subject undergo two dose period . In 7-day dosing period , subject receive oral dos study drug consist open-label CGT 2168 Plavix® order determine randomization schedule . Each period dose administration separate two-week washout period . Study exit occur 1 week Dosing Period 2 . The expected total duration participation 8 week ( 56 day ) , include screen visit within 21 day prior enrollment . On day Day 1 Day 7 dose period , subject admit Phase I unit . Blood sample determine ADP-induced platelet aggregation collect pre-dose Day 1 2 h dose Day 7 . Plasma concentration clopidogrel parent clopidogrel carboxylic acid metabolite also measure pre-dose Day 1 pre-dose serially dose Day 7 .</brief_summary>
	<brief_title>Pharmacodynamics CGT 2168 Compared With Plavix®</brief_title>
	<detailed_description />
	<mesh_term>Clopidogrel</mesh_term>
	<criteria>Healthy male female . Women childbearing potential must negative pregnancy test prior enrollment agree use two method effective barrier contraception , hormonal contraceptive prevent pregnancy throughout study . Able comply study procedure , include return Phase I unit schedule visit procedure . Abstinence tobacco use ( include smoke cessation product contain nicotine ) 90 day prior study entry , agreement abstain tobacco/nicotine use throughout study . Agreement abstain alcohol caffeine ingestion 72 h dose throughout dose period . Able give inform consent , subject sign dated write consent form approve IRB . Hypersensitivity clopidogrel , omeprazole , related drug include inactive ingredient . BMI ( body mass index ) outside range 1930 kg/m2 . At screen , body weight less 50 kg male 45 kg female . Clinically significant abnormal finding physical examination , clinical laboratory test ECG screen . History hypertension 5minute sit screen BP ≥160/100 mmHg measurement repeat twice . History diabetes mellitus , renal failure , acute chronic liver disease , include acute chronic hepatitis , cirrhosis . Positive HIV1 antibody , hepatitis B surface antigen hepatitis C antibody screen test . History clinically significant medical psychiatric condition . Difficulty swallow medication , know suspect gastrointestinal abnormality may affect drug absorption . Participation previous clinical trial within 30 day prior enrollment ( checkin Day 1 Visit 2 ) . Blood donation ≥ 1 pint within 30 day plasma donation within 14 day prior enrollment ( checkin Day 1 Visit 2 ) . Use prescription overthecounter medication ingestion herbal drugs/dietary supplement include vitamin mineral within 14 day prior enrollment ( checkin Day 1 Visit 2 ) . Hormonal contraceptive allow . Subject willing refrain drinking grapefruit juice eat grapefruit throughout study participation . Subject active illicit drug user history illicit drug use within previous 12 month .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2008</verification_date>
	<keyword>Platelet function test</keyword>
	<keyword>Healthy volunteer</keyword>
</DOC>